Two major conventional DC (cDC) subsets have been identified in tumours; cDC1 that specialise in cross-presenting tumour antigens to CD8+ T cells and are associated with improved survival4, and cDC2 that present exogenous antigens to CD4+ T cells and have variable associations with cancer prognosis and treatment responses1. This evidence concerns the gene CD4 and neoplasm.